Abstract
Tamoxifen is a first-line endocrine agent in the mechanism-based treatment of estrogen receptor positive (ER+) mammary carcinoma and applied to breast cancer patients all over the world. Endoxifen is a secondary and highly active metabolite of tamoxifen that is formed among others by the polymorphic cytochrome P450 2D6 (CYP2D6). It is widely accepted that CYP2D6 poor metabolizers exert a pronounced decrease in endoxifen steady-state plasma concentrations compared to CYP2D6 extensive metabolizers. Nevertheless, an in-depth understanding of the chain of cause and effect between CYP2D6 genotype, endoxifen steady-state plasma concentration, and subsequent tamoxifen treatment benefit still remains to be evolved. In this study, physiologically based pharmacokinetic (PBPK)-modeling was applied to mechanistically investigate the impact of CYP2D6 phenotype on endoxifen formation in female breast cancer patients undergoing tamoxifen therapy. A PBPK-model of tamoxifen and its pharmacologically important metabolites N-desmethyltamoxifen (NDM-TAM), 4-hydroxytamoxifen (4-OH-TAM), and endoxifen was developed and validated. This model is able to simulate the pharmacokinetics (PK) after single and repeated oral tamoxifen doses in female breast cancer patients in dependence of the CYP2D6 phenotype. A detailed model-based analysis of the mass balance offered support for a recent hypothesis stating a more prominent role for endoxifen formation from 4-OH-TAM. In the future this model provides a good basis to further investigate the linkage of PK, mode of action, and treatment outcome in dependence of factors such as phenotype, ethnicity, or co-treatment with CYP2D6 inhibitors.
Highlights
Tamoxifen is a first-line endocrine agent in the adjuvant treatment of estrogen receptor positive (ER+)-mammary carcinoma and applied within a regular 5 year therapy regimen to patients all over the world (Fisher et al, 2001; Goetz et al, 2008)
It is widely accepted that cytochrome P450 2D6 (CYP2D6) poor metabolizers exert a pronounced decrease in endoxifen steady-state plasma concentrations compared to CYP2D6 extensive metabolizers
It has been reported in the literature that CYP2D6 poor metabolizers (PM) show a pronounced decrease in endoxifen steady-state plasma concentrations in comparison to CYP2D6 extensive metabolizers (EM; Stearns et al, 2003; Jin et al, 2005; Gjerde et al, 2008; Irvin et al, 2011; Madlensky et al, 2011; Murdter et al, 2011)
Summary
Tamoxifen is a first-line endocrine agent in the adjuvant treatment of estrogen receptor positive (ER+)-mammary carcinoma and applied within a regular 5 year therapy regimen to patients all over the world (Fisher et al, 2001; Goetz et al, 2008) It represents a milestone in the mechanism-based treatment of ER+-breast cancer, there is evidence that not all patients benefit from therapy (Jordan, 2006, 2007). The involvement of the polymorphic CYP2D6 in the formation of the active secondary metabolite endoxifen leads to inter-individual variability in its plasma concentration due to for example single nucleotide polymorphisms affecting CYP2D6 enzyme activity (Zanger et al, 2001; Coller et al, 2002; Stearns et al, 2003; Johnson et al, 2004; Lim et al, 2006). The linkage between CYP2D6 genotype, endoxifen steady-state plasma concentration, and subsequent treatment benefit needs further investigation to achieve an in-depth understanding of the chain of cause and effect (Lash et al, 2009; Fleeman et al, 2011)
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.